Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01446055

Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia

Transplantation of Autologous BM-MNC Processed by ResQ Separator and Conventional Manual Method for Patients With Chronic Limb Ischemia: a Multi-center Randomized Controlled Trial

Sponsor: Hebei Medical University

Conditions Buerger's Disease Critical Limb Ischemia Peripheral Arterial Disease

Interventions Ficoll conventional cell processing method ResQ processed bone marrow sample

Updated 5 times since 2017 Last updated: Oct 8, 2011 Started: Oct 31, 2011 Primary completion: Apr 30, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Buerger's Disease and Critical Limb Ischemia, this trial is ongoing. The trial is conducted by Hebei Medical University and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University
Thermogenesis Corp.
Xuanwu Hospital, Beijing

Data source: Xuanwu Hospital, Beijing

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China